Results 141 to 150 of about 1,428 (167)
Some of the next articles are maybe not open access.
Tofogliflozin: First Global Approval
Drugs, 2014Tofogliflozin (Apleway(®), Deberza(®) [Japan]), an orally active small molecule sodium-glucose co-transporter type 2 (SGLT2) inhibitor, has been developed by Chugai Pharmaceutical for the treatment of type 2 diabetes mellitus (T2DM), and a marketing authorization application was filed in Japan in 2013 by licensees Sanofi K.K. and Kowa.
Raewyn M, Poole, Jennifer E, Prossler
openaire +2 more sources
Effect of Tofogliflozin on Systolic and Diastolic Cardiac Function in Type 2 Diabetic Patients
Cardiovascular Drugs and Therapy, 2019Recent studies have shown that sodium glucose cotransporter 2 (SGLT2) inhibitors have a favorable effect on cardiovascular events in diabetic patients. However, the underlying mechanism associated with a favorable outcome has not been clearly identified.
Kenichi Fujii +2 more
exaly +3 more sources
Expert Opinion on Drug Metabolism and Toxicology, 2016
Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are a new class of drugs that are increasingly used for the management of type 2 diabetes mellitus (T2DM). Among these, tofogliflozin has recently received marketing approval in Japan. Areas covered: In this review, the authors summarize the pharmacokinetic and pharmacodynamic profile of tofogliflozin
Efstratios Maltezos +2 more
exaly +3 more sources
Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are a new class of drugs that are increasingly used for the management of type 2 diabetes mellitus (T2DM). Among these, tofogliflozin has recently received marketing approval in Japan. Areas covered: In this review, the authors summarize the pharmacokinetic and pharmacodynamic profile of tofogliflozin
Efstratios Maltezos +2 more
exaly +3 more sources
Tofogliflozin: A highly selective SGLT2 inhibitor for the treatment of type 2 diabetes
Drugs of Today, 2014Diabetes mellitus impacts a substantial number of people worldwide and despite numerous antidiabetic medications available, approximately half of the drugs do not attain their recommended target, glycated hemoglobin (HbA1c). Recently, the kidney and its role in glucose reabsorption through the sodium/glucose cotransporter 2 (SGLT2) has been the target ...
R F, Rosenwasser +4 more
openaire +2 more sources
Diabetic Medicine, 2021
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to exhibit renoprotective properties [1], even in the absence of diabetes [2]. Promotion of erythropoiesis has been implicated in the mechanism of the beneficial effects of SGLT2 inhibitors on the kidney [1,3,4].
Ken, Sato, Tetsuya, Babazono
openaire +2 more sources
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to exhibit renoprotective properties [1], even in the absence of diabetes [2]. Promotion of erythropoiesis has been implicated in the mechanism of the beneficial effects of SGLT2 inhibitors on the kidney [1,3,4].
Ken, Sato, Tetsuya, Babazono
openaire +2 more sources
Metabolism and mass balance of SGLT2 inhibitor tofogliflozin following oral administration to humans
Xenobiotica, 20131. Tofogliflozin is a novel and selective SGLT2 inhibitor increasing glucosuria by inhibition of glucose re-absorption in the kidney for the treatment of type 2 diabetes mellitus. 2. In this study, the metabolism and the mass balance of tofogliflozin was evaluated following administration of a single oral dose of 20 mg [(14)C]-tofogliflozin to six ...
Manfred, Zell +8 more
openaire +2 more sources
Clinical Pharmacokinetics, 2013
Human mass balance studies and the assessment of absolute oral bioavailability (F) are usually assessed in separate studies. Intravenous microdose administration of an isotope tracer concomitant to an unlabeled oral dose is an emerging technique to assess F.
Dietmar, Schwab +4 more
openaire +2 more sources
Human mass balance studies and the assessment of absolute oral bioavailability (F) are usually assessed in separate studies. Intravenous microdose administration of an isotope tracer concomitant to an unlabeled oral dose is an emerging technique to assess F.
Dietmar, Schwab +4 more
openaire +2 more sources